摘要
目的:探讨放射性核素氯化锶(89SrCl2)与唑来膦酸联合治疗转移性骨肿瘤的临床效果。方法:采用随机、双盲、双模拟和多中心的实验设计方法。采用随机方法将97例转移性骨肿瘤患者分为两组,单项治疗组51例,采用89SrCl2治疗;联合治疗组46例,用89SrCl2与唑来膦酸治疗,观察疗效。结果:89SrCl2单项治疗组51例患者,治疗后疼痛反应有效27.5%(14/51),显效49.0%(25/51),总有效率达76.5%(39/51);骨转移灶治疗后有效5.9%(3/51),显效27.4%(14/51),总有效率达到33.3%(17/51)。89SrCl2与唑来膦酸联合治疗组46例患者,治疗后疼痛反应有效41.3%(19/46),显效50.0%(23/46),总有效率达91.3%(42/46);骨转移灶治疗后有效6.5%(3/46),显效32.6%(15/46),总有效率达到39.1%(18/46)。联合治疗组止痛的疗效高于单项治疗组,差异有统计学意义,P<0.05;消退转移灶的疗效与单项治疗组相同。结论:89SrCl2与唑来膦酸对转移性骨肿瘤所致疼痛有明显疗效,同时还可部分消退转移病灶,且安全无不良反应,联合治疗效果优于89SrCl2单项治疗。
OBJECTIVE：To explore the clinical effectiveness of the radioactive nuclide strontium chloride and zoledronic acid in the treatment of transferable bone tumor.METHODS：Ninty-seven patients with transferability bone tumor were divided into 2 groups at random：51 patients were treated with 89SrCl2 in the single item treatment group;46 patients who were included in therapeutic alliance were the target of 89SrCl2 and zoledronic acid＇s union treatment.RESULTS：The single term：27.5%（14/51）patients＇ pain reaction was considered as effectiveness,49.0%（25/51）patients were appeared,and the total effectiveness was 76.5%（39/51）;5.9%（3/51）of transferability bone tumors were realized as effectiveness,27.4%（14/51）of ones were appeared,and the total effectiveness was 33.3%（17/51）.The union term：41.3%（19/46）patients＇ pain reaction was consided as effectiveness,50.0%（23/46）patients were appeared,and the total effectiveness was 91.3%（42/46）;6.5%（3/46）of transferability bone tumors were realized as effectiveness,32.6%（15/46）of ones were appeared,and the total effectiveness was 39.1%（18/46）.The latter was better than the former（P0.05）.CONCLUSION：About the pain that transferable bone tumor result in,the 89SrCl2 and zoledronic acid＇ union therapy has an obvious curative effect,meanwhile,can partly decrease the focus of disease,and then it is thought as safety and reliability.
出处
《中华肿瘤防治杂志》
CAS
2010年第4期293-295,共3页
Chinese Journal of Cancer Prevention and Treatment
